君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌_老虎社区_美港股上老虎

君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌

界面2023-10-28

10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

丁丁的山月
·2023-10-28
首款PDA批准了，破冰之旅，前景可以看好了
回复
点赞
举报

热议股票

7x24

全部

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"share":"https://www.laohu8.com/m/news/2378338723?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2023-10-28 08:29","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2378338723","market":"hk","top_or_hot":-1,"title":"君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌","media":"界面","content":"<div>\n<p>10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-28 08:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b><strong>界面</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688180","symbol_name":"君实生物","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b","article_id":"2378338723","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2378338723","pubTimestamp":1698452971,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab之后君实生物第二个获得FDA商业化批准的产品。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688180":"君实生物","BK1515":"抗疫概念","BK1583":"高瓴概念","01877":"君实生物","BK1161":"生物科技"},"translate_title":"Junshi Bio-Treprizumab was approved by FDA for the treatment of nasopharyngeal carcinoma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688180":0.9,"01877":1},"content_text":"10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab之后君实生物第二个获得FDA商业化批准的产品。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[{"id":235272471425040,"gmtCreate":1698461570396,"gmtModify":1698469505372,"author":{"id":"3451967978755494","authorId":"3451967978755494","name":"丁丁的山月","avatar":"https://static.tigerbbs.com/92acd124175395799a4a8e35cdf295fe","vip":1,"crmLevel":2,"crmLevelSwitch":0},"htmlText":"首款PDA批准了，破冰之旅，前景可以看好了","listText":"首款PDA批准了，破冰之旅，前景可以看好了","text":"首款PDA批准了，破冰之旅，前景可以看好了","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/235272471425040","repostId":2378338723,"repostType":2,"repost":{"id":"2378338723","pubTimestamp":1698452971,"share":"https://www.laohu8.com/m/news/2378338723?lang=&edition=full","pubTime":"2023-10-28 08:29","market":"hk","language":"zh","title":"君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2378338723","media":"界面","summary":"10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab之后君实生物第二个获得FDA商业化批准的产品。","content":"<div>\n<p>10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b\">Web Link</a>\n\n</div>\n","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n君实生物特瑞普利单抗获美国FDA批准，用于治疗鼻咽癌\n</h2>\n\n<h4 class=\"meta\">\n\n\n2023-10-28 08:29 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b><strong>界面</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"688180":"君实生物","01877":"君实生物","BK1515":"抗疫概念","BK1161":"生物科技","BK1583":"高瓴概念"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023102808293182ffb320&s=b","is_english":false,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2378338723","content_text":"10月28日，生物医药公司Coherus BioSciences与君实生物宣布，美国食品和药品管理局（FDA）批准其单抗Loqtorzi（toripalimab，特瑞普利单抗）联合吉西他滨/顺铂作为晚期复发或转移性鼻咽癌（NPC）成年患者的一线治疗。其单药也获批用于复发或转移性鼻咽癌含铂治疗后的二线及以上治疗。新闻稿称，特瑞普利单抗是首款FDA批准用于治疗鼻咽癌的药物，也是继etesevimab之后君实生物第二个获得FDA商业化批准的产品。","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":0,"commentSize":1,"repostSize":1,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}